Abstract

2501 Background: The anaplastic lymphoma kinase (ALK) fusion gene is a key oncogenic driver in a subset of patients with NSCLC. Crizotinib is a potent and selective, ATP-competitive, small molecule ALK inhibitor. Patients with ALK-positive NSCLC may benefit from targeted ALK inhibitors. Methods: An ongoing open-label, multicenter, 2-part, phase I trial is investigating the safety, tolerability, pharmacokinetics, and antitumor activity of crizotinib in patients with advanced cancer. Updated safety and response data and preliminary PFS data from an expanded ALK-positive cohort of patients with NSCLC in part 2 of the study are reported. Patients received oral crizotinib 250 mg BID in 28-day cycles. Results: Currently, 119 patients with ALK-positive NSCLC have enrolled and 116 are evaluable for response, with 94 in follow-up for survival. Median age was 51 years; patients were usually never- or former-smokers (99%) with adenocarcinoma histology (97%). Most patients were heavily pretreated, with 44% receiving ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call